Qiagen Draws Early Takeover Interest from EQT, Advent, and KKR No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation. Credit: Jasper Juinen/Bloomberg Subscribe now Already have an account? Sign in.
